Voriconazole Tipsheet

The following information is intended for use by providers who are attempting to prescribe Voriconazole to Biobank participants with certain CYP2C19 genetic variants.  

For further information about Voriconazole and CYP2C19, please click here

If you have questions, please call the pharmacogenomics consult pager at (303) 266-4510.

Screen Shot 2022-02-15 at 8.43.01 AM Screen Shot 2022-02-15 at 8.43.14 AM

References:

  1. https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/
  2. Miller MA, Lee YM. Applying Pharmacogenomics to Antifungal Selection and Dosing- Are We There Yet? Curr Fungal Infect Rep. 2020; 14(1): 63-75.
  3. Obeng AO, et al. CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics? Pharmacotherapy. 2014; 34(7): 703-18.
  4. Lamoureux F, et al. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. Int J Antimicrob Agents. 2016; 47(2): 124-31.
  5. Hamadeh IS, et al. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections. Pharmacogenet Genomics. 2017; 27(5): 190-6.
Did you find this information useful?